News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
683,841 Results
Type
Article (38994)
Company Profile (277)
Press Release (644570)
Section
Business (203839)
Career Advice (1987)
Deals (35362)
Drug Delivery (84)
Drug Development (80781)
Employer Resources (168)
FDA (16086)
Job Trends (14800)
News (344500)
Policy (32434)
Tag
Academia (2530)
Alliances (49041)
Alzheimer's disease (1217)
Approvals (16006)
Artificial intelligence (122)
Bankruptcy (352)
Best Places to Work (11479)
Biotechnology (196)
Breast cancer (109)
Cancer (948)
Cardiovascular disease (82)
Career advice (1657)
Cell therapy (208)
Clinical research (63966)
Collaboration (334)
Compensation (171)
COVID-19 (2522)
C-suite (82)
Data (903)
Diabetes (138)
Diagnostics (6106)
Earnings (84353)
Employer resources (146)
Events (109056)
Executive appointments (254)
FDA (16544)
Funding (298)
Gene therapy (153)
GLP-1 (562)
Government (4319)
Healthcare (18659)
Infectious disease (2600)
Inflammatory bowel disease (102)
Interviews (308)
IPO (16274)
Job creations (3623)
Job search strategy (1415)
Layoffs (409)
Legal (7848)
Lung cancer (156)
Manufacturing (157)
Medical device (13150)
Medtech (13155)
Mergers & acquisitions (19122)
Metabolic disorders (369)
Neuroscience (1459)
NextGen Class of 2024 (6497)
Non-profit (4463)
Northern California (1262)
Obesity (219)
Opinion (176)
Patents (96)
People (56150)
Phase I (19846)
Phase II (28163)
Phase III (21029)
Pipeline (254)
Postmarket research (2553)
Preclinical (8445)
Radiopharmaceuticals (234)
Rare diseases (187)
Real estate (5888)
Regulatory (21457)
Research institute (2307)
Resumes & cover letters (349)
Southern California (1128)
Startups (3561)
United States (12068)
Vaccines (539)
Weight loss (161)
Date
Today (226)
Last 7 days (918)
Last 30 days (3161)
Last 365 days (35543)
2024 (30913)
2023 (40074)
2022 (51173)
2021 (55712)
2020 (54087)
2019 (46543)
2018 (35021)
2017 (32112)
2016 (31480)
2015 (37552)
2014 (31321)
2013 (26345)
2012 (28571)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (187)
Asia (37039)
Australia (6058)
California (2853)
Canada (1195)
China (217)
Colorado (126)
Connecticut (126)
Europe (79292)
Florida (408)
Georgia (102)
Illinois (312)
Indiana (184)
Kansas (95)
Maryland (538)
Massachusetts (2333)
Michigan (144)
Minnesota (254)
New Jersey (851)
New York (863)
North Carolina (673)
Northern California (1262)
Ohio (129)
Pennsylvania (772)
South America (1091)
Southern California (1128)
Texas (399)
Utah (82)
Washington State (328)
683,841 Results for "progenity inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment
Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”)(Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a definitive agreement with ProGen Co., Ltd.
June 24, 2024
·
7 min read
Business
Progenity to Report First Quarter Financial Results and Provide Corporate Update as Biora Therapeutics, Inc.
Progenity, Inc. (Nasdaq: PROG) today announced that it will report first quarter ended March 31, 2022 financial results on Tuesday, May 10, 2022 after the close of financial markets.
May 3, 2022
·
1 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Press Releases
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
Verrica Pharmaceuticals Inc. today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).
July 1, 2024
·
5 min read
Lophos Holdings Inc. Announces the Completion of Securities Purchase Agreement with ThreeD Capital Inc.
Lophos Holdings Inc. (CSE: MESC) (“Lophos” or the “Company”), a Canadian bioscience company focused on the cultivation and sale of Lophophora williamsii (“Peyote”) and ThreeD Capital Inc. (CSE: IDK) (OTCQB: IDKFF) (“ThreeD”), a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, are pleased to announce the completion of its previously announced Securities Purchase Agreement (the “Agreement”).
June 20, 2024
·
4 min read
Press Releases
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)
October 8, 2024
·
14 min read
Biotech Beach
Progenity to Become Biora Therapeutics as it Completes Transformation
Progenity, Inc. announced that it will change its name to Biora Therapeutics, Inc. during the second quarter of 2022, to better reflect the company’s focus on developing its pipeline for targeted and systemic oral delivery of biotherapeutics.
April 12, 2022
·
1 min read
Press Releases
CorMedix Inc. to Participate in the Truist Securities BioPharma Symposium
November 4, 2024
·
1 min read
Press Releases
Boston Scientific Announces Agreement to Acquire Cortex, Inc.
November 5, 2024
·
7 min read
Vivos Inc. Submits the Application to the FDA for Authority to Initiate Human Clinical Trials
Vivos Inc. (OTCQB: RDGL), Vivos Inc. filed the application for an Investigational Device Exemption (“IDE”).
June 28, 2024
·
4 min read
1 of 68,385
Next